|
|
|
|
|
Highlights from the American Society of Radiation Oncology (ASTRO) Annual Meeting |
|
|
|
|
|
|
| Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology
|
| Jonathan Tward, MD, PhD, FASTRO
|
| The 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting held in San Antonio, TX between October 23rd and 26th, 2022 was host to a plenary session with Dr. Jonathan Tward discussing prostate cancer risk stratification using multimodal deep learning with digital histopathology, within the context of NRG Oncology phase III trials.
|
|
|
|
|
|
| Improving Outcomes for High Risk Prostate Cancer
|
|
| Association of PSA Screening Rates and Subsequent Metastatic Prostate Cancer Incidence in a National Healthcare System
|
| Alex Bryant, MD, MS
|
| In this session that addressed studies aimed at improving outcomes for high-risk prostate cancer patients, Dr. Alex Bryant presented results of his team’s work evaluating the association of PSA screening rates and subsequent metastatic prostate cancer incidence rates within the context of the Veterans Affairs Healthcare System.
|
|
|
|
|
|
| Phase III Trial of Dose Escalated Radiation Therapy and Standard ADT vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High Risk Prostate Cancer (NRG Oncology/RTOG 1115)
|
| Dror Michaelson, MD, Ph.D.
|
| Dr. Marc Dror Michaelson presented the primary analysis of a phase III trial of dose escalated radiation therapy and standard ADT versus dose escalated radiation therapy and enhanced ADT with TAK-700 (orteronel) for men with high-risk prostate cancer (NRG Oncology/RTOG 1115).
|
|
|
|
|
|
|
|
|
|
|
| Sequencing of ADT of Short Duration with Radiotherapy for Non-Metastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
|
| Ting Martin Ma, MD, Ph.D.
|
| In this presentation, Dr. T. Martin Ma presented results of the SANDSTORM meta-analysis, which evaluated the sequencing of short-term ADT with radiotherapy in patients with non-metastatic prostate cancer.
|
|
|
|
|
|
| Optimal Duration of ADT with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium
|
| Nicholas Zaorsky, MD
|
| The ideal duration of concurrent ADT use in patients receiving radiation therapy is currently unknown. The treating physician must balance the improvement in prostate cancer-specific mortality in longer treatment regimens with the subsequent worsening of other-cause mortality rates. In this presentation, Dr. Nicholas Zaorsky presented results of a MARCAP meta-analysis evaluating the optimal duration of ADT with definitive radiotherapy for prostate cancer patients.
|
|
|
|
|
|
| Predictive Value of Ga68-PSMA PETCT-Based Response to Neoadjuvant Androgen Deprivation Therapy in Node Positive Prostate Cancer Treated with Radical Radiotherapy
|
| Vedang Murthy, MD, DNB, DipEPP
|
| In this presentation, Dr. Vedang Murthy presented the results of his group’s study evaluating the predictive value of 68Ga-PSMA PET/CT-based response to neoadjuvant ADT in node-positive prostate cancer patients treated with radical radiotherapy. This study included 92 eligible patients with paired PSMA PET/CTs pre- and post-neoadjuvant ADT. The median duration of neoadjuvant ADT was 6 months and that of total ADT was 24 months.
|
|
|
|
|
|
| Genitourinary Posters - New Insights Into Post-Prostatectomy Radiotherapy
|
|
| PSMA PET/CT–Based Atlas for Prostatic Bed Recurrence of Prostate Cancer after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy
|
| Alan Dal Pra, MD
|
| The 2022 ASTRO annual meeting featured a session on new insights into post-prostatectomy radiotherapy, including a presentation by Dr. Alan Dal Pra discussing PSMA PET/CT–based atlas for prostatic bed recurrence of prostate cancer after radical prostatectomy. At ASTRO 2022, Dr. Dal Pra and colleagues presented their analysis of the patterns of recurrence in the prostate bed of prostate cancer patients with biochemical recurrence after radical prostatectomy using 68Ga-PSMA-11 PET/CT (PSMA PET). They also evaluated patterns of PSMA PET recurrence in relation to the RTOG-based clinical target volumes definition.
|
|
|
|
|
|
| Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial PSMA SRT
|
| Wesley R. Armstrong, MD
|
| In this presentation by Wesley Armstrong he presented results from the prospective randomized phase 3 trial PSMA SRT. The purpose of the randomized PSMA SRT trial is to compare the success rate of salvage radiation therapy for recurrence of prostate cancer after radical prostatectomy with (intervention arm) and without (control arm) planning based on PSMA PET/CT. At the ASTRO 2022 meeting, Armstrong and colleagues reported the secondary endpoint of the trial: impact of PSMA PET/CT on the treatment plan.
|
|
|
|
|
|
 |
